3Kanazawa F, Koizumi F, Koh Y ,et al. In vitro synergistic interac- tions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this in- teraction. Clin Cancer Res, 2001,7 : 202-209.
4Miller AB, Hoogstraten B ,Staquet M ,et al, Reporting results of cancer treatment. Cancer, 1981,47 : 207-214.
5Tzioras S, Pavlidis N, Paraskevaidis E, et al. Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev ,2007, 33:24-38.
6Katsumata N,Yoshikawa H,Hirakawa T,et al. Phase nI random- ized trial of neoadjuvant chemotherapy (NAC) followed by radi- cal hysterectomy (RH) versus RI-/for bulky stage I/II in cervi- cal cancer(JCOG0102). Proc Am Soc Clin Oncol,2006,24 (S 18) : 1.
7Eddy GL,Bundy BN,Creasman WT,et al. Treatment of (bulky) stage IB cervical cancer with or without neoadjuvant vincristine and eisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy:a phase III trial of the Gynecologic Oneology Group. Gynecol Oncol, 2007,106 : 362-369.
5LARSSON A,FLODIN M,HANSSON L O,et al.Patient selec-tion has a strong impact on cystatin C and modification of diet inrenal disease(MDRD)estimated glomerular filtration rate[J].Clin Biochem,2008,41(16/17):1355-1361.
6BAXMANN A C,AHMED M S,MARQUES N C,et al.Influenceof muscle mass and physical activity on serum and urinary creati-nine and serum cystatin C[J].Clin J Arn Soc Nephrol,2008,3(2):348-354.
7WOMER R B,PRITCHARD J,BARRATT T M.Renal Toxicityof cisplatin in children[J].J Pediatr,1985,106(2):659-663.
8DAUGAARD G,ROSSING N,RORTH M.Effects of cisplatin ondifferent measures of glomerular function in the human kidney withspecial emphasis on high dose[J].Cancer Chemother Pharmacol,1988,21(3):163-167.
10Loizzi V, Cormio G, Vicino M, et al. Neoadjuvant chemotherapy : an alternative option of treatment for locally advanced cervical cancer[ J]. Gynecol Obstet Invest, 2008,65 (2) :96-103.
